Dr. Murrough is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Gustave L Levy Pl
Box 1230
New York, NY 10029Phone+1 212-585-4640Fax+1 212-241-3354
Summary
- Dr. James Murrough is Professor of Psychiatry and Neuroscience and Director of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai. He is a faculty member of the Friedman Brain Institute. Dr. Murrough conducts clinical and translational research aimed at understanding the biological basis of mood and anxiety disorders in order to point the way towards new, more effective treatments. He received his Bachelor of Science in Neuroscience and Behavioral Biology from Emory University in Atlanta and his Medical degree from Tufts University School of Medicine in Boston. He completed residency training in psychiatry, a research fellowship in experimental therapeutics and clinical neuroscience, and a PhD in clinical research from Mount Sinai. Dr. Murrough has received research support from the National Institutes of Health, the Doris Duke Charitable Foundation, the American Foundation for Suicide Prevention, the Dana Foundation and the Brain and Behavior Research Foundation. He is a Member of the American College of Neuropsychopharmacology and an active member of the scientific community. In addition to his research and educational activities, Dr. Murrough oversees a clinical program at Mount Sinai focused on evidence-based treatments for treatment-resistant depression and other refractory forms of mood and anxiety disorders.
Education & Training
- Icahn School of Medicine at Mount SinaiFellowship, Research, 2009 - 2011
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 2005 - 2009
- Tufts University School of MedicineClass of 2005
Certifications & Licensure
- NY State Medical License 2007 - 2026
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Continuation Ketamine in Major Depression Start of enrollment: 2007 Oct 01
- Cysteamine Therapy for Major Depressive Disorder Start of enrollment: 2008 Jul 01
- Treatment Study of Bipolar Depression Start of enrollment: 2009 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D tri...Gerard Sanacora, Brian S Barnett, Bo Hu, Fernando S Goes, Sanjay J Mathew
Psychiatry Research. 2025-05-01 - Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia.Laurel S Morris, Sara Costi, Sara Hameed, Katherine A Collins, Emily R Stern
Molecular Psychiatry. 2025-03-25 - Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression and Anhedonia in Major Depress...Avijit Chowdhury, Sarah Boukezzi, Sara Costi, Sara Hameed, Yael Jacob
Biological Psychiatry. 2025-03-04
Journal Articles
- Effects of the KCNQ Channel Opener Ezogabine on Functional Connectivity of the Ventral Striatum and Clinical Symptoms in Patients with Major Depressive DisorderKatherine A Collins, Dan V Iosifescu, James W Murrough, Eric J Nestler, Nisha Chadha, Nature
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
- High-Dose Ondansetron Reduces Activation of Interoceptive and Sensorimotor Brain RegionsEvan Leibu, Wayne K Goodman, James W Murrough, Barbara J Coffey, Nature
- Join now to see all
Authored Content
- F142. Effect of Treatment Resistance Status on Whole Brain Voxel-Based Morphometry in Major Depressive DisorderApril 2018
Press Mentions
- Ketamine Beats Shock Therapy in Easing Tough-to-Treat DepressionMay 25th, 2023
- AAGP Session to Highlight Research on Resilience, Emotional Well-Being in AgingJanuary 27th, 2023
- Plastic Surgeons Are Using Ketamine to Make Nose Jobs More PleasantJanuary 18th, 2022
- Join now to see all
Grant Support
- Neural Circuit-Specific Mechanisms of Ketamine's Effect on Anhedonia and Anxiety in Depression Using Ultra-High Field 7-Tesla MRIICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2023–2028
- Biomarker-Guided Antidepressant Selection for Treatment-Resistant DepressionWEILL MEDICAL COLL OF CORNELL UNIV2024–2026
- Influence of Dietary Botanical Supplements on Biological and Behavioral ResilienceICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2020–2025
- Developing Neuronal KCNQ Channel Modulators for Mood DisordersICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2017–2025
External Links
- Depression and Anxiety Centerhttp://www.icahn.mssm.edu/dac
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: